Kaiser Permanente to Evaluate Neopath's AutoPap 300 QC System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

REDMOND, Wash--NeoPath Inc has signed an agreement with Kaiser Permanente to install AutoPap 300 QC Systems at its Northern California facility. Following a successful evaluation, Kaiser Permanente anticipates making the technology available to its nearly 2.5 million Northern California members.

REDMOND, Wash--NeoPath Inc has signed an agreement with KaiserPermanente to install AutoPap 300 QC Systems at its Northern Californiafacility. Following a successful evaluation, Kaiser Permanenteanticipates making the technology available to its nearly 2.5million Northern California members.

The AutoPap System rescreens Pap smear slides initially classifiedas normal, using high-speed image processing computers, videoimaging technology, and image interpretation software. In clinicaltrials in US laboratories, the system improved the detection rateof false-negative smears.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
Related Content